**Abstract**

**Objective:** Nosocomial and community acquired multidrug resistant *Klebsiella* infections are widespread resulting in high morbidity and mortality due to limited number of antibiotics treatment options. This study investigated efflux pump activity, biofilm forming potential and antibiotic susceptibility profile of *Klebsiella* spp. isolated from clinical samples in a tertiary hospital in Lagos Nigeria. Eighteen clinical *Klebsiella* spp. isolated from urine, blood and sputum were subjected to antibiotic susceptibility testing using the disc diffusion method. Efflux pump activity was evaluated by the ethidium bromide cartwheel method and biofilm forming ability was determined by the tissue culture plate technique.

**Results:** All 18 (100%) *Klebsiella* isolates were resistant to cefuroxime, cefixime, amoxicillin–clavulanate, ampicillin+cloxacillin, cefotaxime, and imipenem. Seventeen (94.4%) were resistant to ofloxacin while sixteen (88.9%) were resistance to nalidixic acid, Gentamicin and levofloxacin. All *Klebsiella* isolates possessed active efflux pump with the ability to form biofilm. However, their biofilm forming capabilities varied as 4 (22.2%) were strong, 3 (16.7%) were moderate and 11 (61.1%) were weak biofilm formers. Findings in this study reveal multiple factors at play in mediating the high level of antibiotic resistance observed in *Klebsiella* isolates. Hence a multifaceted approach is advocated in managing the infections caused by the pathogen.

**Keywords:** Efflux pump, Biofilm, Antibiotic resistance, Klebsiella

**Introduction**

Among pathogenic Gram-negative bacteria that belong to the family Enterobacteriaceae, the genus *Klebsiella* consist of species known to cause community-acquired and nosocomial infections including urinary tract infections (UTIs), pneumonia, sepsis and bloodstream infection. With the emergence of antibiotic resistant and hyper-virulent *Klebsiella* strains, infections they cause result in high morbidity and mortality majorly in high risk individuals including immunocompromised, neonates and the elderly [1–4]. Several studies have reported multidrug resistant *Klebsiella* strains isolated from clinical cases. Rath and Padhy [5], reported a high prevalence of multidrug resistant *K. oxytoca* and *K. pneumonia* isolated from an Indian teaching hospital and adjoining community. Strains were resistant to fluoroquinolones, carbapenem, third and fourth generation cephalosporins. In a similar study, Fadeyi et al. [6] in Nigeria reported *Klebsiella* spp. of clinical origin that displayed high resistance to ceftazidime (100%), cefotaxime (94.0%), ciprofloxacin (70.0%) and trimethoprim-sulphamethoxazole (92.0%). However,
no resistance to carbapenem was recorded. Biofilm formation has been linked to antimicrobial resistance and persistence observed in several pathogenic Gram negative bacteria including *Klebsiella* species [7]. Biofilm is an aggregation of sessile microorganisms enclosed in a matrix of extracellular polymeric substances. Their prevalence in medical implants, living and dead tissues make infection they cause difficult and expensive to treat [8]. Another factor that mediates antibiotic resistance in bacteria is the possession of active efflux pumps. Efflux pump systems expel a large array of chemical compounds including antibiotics from bacteria cells that possess them in an energy dependent manner [9]. It has been reported that efflux pump activity is connected to biofilm formation with a whole resultant effect of amplified antibiotic resistance [8] (Reza et al. 2019). Hence this study seeks to evaluate the efflux pump activity, biofilm formation and antibiotic resistance profiles of *Klebsiella* spp. isolated from clinical samples in a tertiary hospital in Lagos Nigeria.

**Main text**

A total of eighteen *Klebsiella* isolates were obtained from Lagos University Teaching Hospital, Iddiaraba Lagos Nigeria. Isolates were re-identified using standard biochemical tests according to Cheesebrough [10].

**Methodology**

Antimicrobial susceptibility testing was carried out according to European Committee on Antimicrobial Susceptibility Testing [11], guidelines using the disc diffusion method. Eleven antibiotics including cefuroxime, gentamicin, cefixime, ofloxacin, amoxicillin−clavulanate, nalidixic acid, cefotaxime, ampicillin + cloxacillin, nitrofurantoin, imipenem and levofloxacin were used. Using a sterile cotton swab, one or two colonies of isolates were emulsified in normal saline and adjusted to 0.5 McFarland standard which was then applied onto the surface of Muller-Hinton agar. Antibiotic discs were then applied and incubated at 37 °C for 24 h. *E. coli* ATCC 25922 was used as for quality control.

Efflux pump activity of isolates was determined according to the method of Martins et al. [9] using the ethidium bromide (EtBr) cartwheel method. Cell suspension of isolates with approximately 10⁶ cells per mL were streaked on Muller-Hinton agar plates containing 0 mg/L, 0.5 mg/L, 1 mg/L, 1.5 mg/L and 2 mg/L concentrations of EtBr and incubated at 37 °C for 24 h. After which bacteria culture were viewed under a UV trans-illuminator (Cleaver Scientific Ltd) for fluorescence. Agarose gels that contained EtBr were dried and put in plastic bags which were then collected by the waste disposal unit for onward disposal.

Ability of isolates to form biofilm was determined by the tissue culture plate technique of Stephanovic et al. [12]. Single colonies of each *Klebsiella* isolate were inoculated into brain heart infusion (BHI) broth (Oxoid, Basingstoke, UK) supplemented with 2% sucrose and 200 μL of bacterial suspension was loaded into the individual wells of 96-well microtiter plate. Two hundred microlitre of sterile BHI broth was used as negative control. After 24 h incubation at 37 °C content of each well was discarded and wells were washed three times with sterile deionized water to remove non-adherent bacteria. Wells were air-dried for 45 min and 200 μL of 0.1% (v/v) crystal violet solution was added to each well and incubated for 45 min at room temperature then wells were again washed four times with sterile deionized water. Thirty-three percent glacial acetic acid was added to wells to solubilize incorporated dye. The optical density (OD) of stained adherent bacteria was measured at 650 nm using the Emax® Plus Microplate Reader (Molecular Devices San Jose, CA). The assay was performed in triplicate.

**Results**

All eighteen (100%) *Klebsiella* isolates showed resistance to cefuroxime, cefixime, amoxicillin−clavulanate, ampicillin + cloxacillin, cefotaxime, and imipenem. Seventeen (94.4%) were resistant to ofloxacin while sixteen (88.9%) were resistance to nalidixic acid, gentamicin and levofloxacin. Only thirteen (72.2%) were resistant to nitrofurantoin as shown in Fig. 1.

All *Klebsiella* spp. isolates were positive for efflux pump activity as they fluorescence under UV light at 0.5 mg/L EtBr concentration. However only four (22.2%) were strong biofilm formers, while three (16.7%) and eleven...
(61.1%) were moderate and weak biofilm formers respectively. All strong biofilm formers were Klebsiella spp. isolated from urine, though others also isolated from urine were are moderate and weak biofilm formers as shown in Table 1.

Two isolates (K51 and K68) that were strong biofilm formers and exhibited efflux pump activity displayed pan resistance to all eleven test antibiotics. Although isolates K52, K53, K59 isolated from urine and isolates K63, K64 isolated from sputum that were weak biofilm formers with efflux pump activity were also resistant to all eleven test antibiotics.

**Discussion**

Hospital and community acquired infections caused by Klebsiella spp. are widespread and are becoming difficult to treat due to antibiotic resistance and biofilm formation ability of this pathogen [13, 14]. In this study Klebsiella spp. isolated from urine, blood and sputum showed high (100%) resistance to cefuroxime, cefixime, amoxicillin – clavulante, ampicillin + cloxacillin, cefotaxime, and imipenem. Previous studies in Nigeria have also documented high and extensive resistance of Klebsiella spp. to β-lactam antibiotics [15–18]. Globally, resistance of Klebsiella spp. to β-lactam antibiotics including carbapenem is rife. Huai et al. [19] reported Klebsiella pneumoniae isolates that had high rate of resistance to imipenem in China. Similarly, Yazdansetad et al. [20] a 50% rate of extended spectrum β-lactamase (ESBL) producing K. pneumoniae in Iran. In this study Klebsiella spp. also had considerable resistance to other antibiotics including ofloxacin (94.4%), nitrofurantoin (72.2%) and 88.9% resistance to nalidixic acid, gentamicin and levofloxacin. This is similar to the findings of Fadeyi et al. [6] and Humayun et al. [21] that reported the resistance of Klebsiella spp. to fluoroquinolone, aminoglycoside and sulfamethoxazole in Nigeria and Pakistan respectively. Several mechanisms have been deployed over time by bacteria pathogens in evading the action of antibiotics. One of such mechanism is possessing active efflux pumps which was detected in all Klebsiella spp. isolates investigated in this study. Thus it could be asserted that active efflux pump played a role in the observed level of antibiotic resistance. Szabo et al. [22] and Maurya et al. [23] reported the role of efflux pump in quinolone and β-lactam antibiotic resistance in Klebsiella pneumoniae strains isolated from clinical samples in Hungary and India respectively. Klebsiella spp. are known to form biofilm which enhances their virulence and resistance to antibiotics [13]. Nirwati et al. [24] reported strong (26.95%), moderate (28.74%) and weak (29.94%) biofilm forming K. pneumoniae isolates that were extensively resistant to antibiotics in tertiary care hospital in Indonesia. This is similar to our findings in this study although

| Isolate ID | Source | Biofilm forming potential | Efflux pump activity | Antibiotic resistance profile |
|-----------|--------|---------------------------|----------------------|------------------------------|
|           |        | Strong Moderate Weak      | Phenotypic           | CXM AUG CTX IMI OFL GEN NA NIT ACX ZEM LBC |
| K51       | Urine  | ✓                          | +                    | R R R R R R R R R R R R |
| K52       | Urine  | ✓                          | +                    | R R R R R R R R R R R R |
| K53       | Urine  | ✓                          | +                    | R R R R R R R R R R R R |
| K54       | Urine  | ✓                          | +                    | R R R R R R S R R R R R |
| K55       | Urine  | ✓                          | +                    | R R R R R R S R R R R R |
| K56       | Urine  | ✓                          | +                    | R R R R R R R R R R R R |
| K57       | Urine  | ✓                          | +                    | R R R R R S R R R R R R |
| K58       | Urine  | ✓                          | +                    | R R R R R R S R R R R R |
| K59       | Urine  | ✓                          | +                    | R R R R R R R R R R R R |
| K60       | Urine  | ✓                          | +                    | R R R R S R S R R S S |
| K61       | Urine  | ✓                          | +                    | R R R R R R S R S R S |
| K62       | Blood  | ✓                          | +                    | R R R R R R S R R R R |
| K63       | Sputum | ✓                          | +                    | R R R R R R R R R R R R |
| K64       | Sputum | ✓                          | +                    | R R R R R R R R R R R R |
| K65       | Urine  | ✓                          | +                    | R R R R R R R R S R R |
| K66       | Urine  | ✓                          | +                    | R R R R R R R R R R R R |
| K67       | Urine  | ✓                          | +                    | R R R R R R R S R R R |
| K68       | Urine  | ✓                          | +                    | R R R R R R R R R R R R |

CXM cefuroxime, GEN gentamicin, ZEM gefixime, OFL ofloxacin, AUG amoxicillin – clavulanate, NA nalidixic acid, CTX cefotaxime, ACX ampicillin + cloxacillin, NIT nitrofurantoin, IMI imipenem, LBC levofloxacin
with slight variation of having 61.1% weak biofilm formers. However it was observed that the strength of biofilm formation be it strong, moderate or weak did not exclusively influence pan resistance to all test antibiotics used. This can be related to the study of Alcántar-Curiel et al. [25] in Mexico that reported no direct association of biofilm formation and ESBL production in multidrug resistant nosocomial *K. pneumonia* isolates.

**Conclusion**

Multiple factors at play can generally amplify antibiotic resistance in bacterial pathogens as observed in this study. Hence there should be a multifaceted approach such as use of efflux pump inhibitors and biofilm disruptors in combination with antibiotic therapy in tackling the problem. Also routine surveillance should be a thing of priority in health care and community settings to curb the continuous transmission of antibiotic resistant *Klebsiella spp.*

**Limitation of study**

It would be difficult to make far reaching conclusion as the number of isolates in this study are few. Hence future study should cover more hospital and investigate a larger number of isolates.

**Abbreviations**

ESBL: Extended spectrum beta lactamase; EtBr: Ethidium bromide; UV: Ultra violet; UTIs: Urinary tract infections.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

Conception and design: AAI, SSI; Laboratory experiment: AS, AA; Result Analysis and manuscript writing/review: AS, AA, AAI, SSI. All authors read and approved the final manuscript.

**Funding**

None.

**Availability of data and materials**

All data obtained are available within the article.

**Ethics approval and consent to participate**

Ethical approval for this study was obtained from the Institutional Review Board, Nigerian Institute of Medical Research with code number IRBB/19/033.

**Consent for publication**

Not applicable.

**Competing Interests**

There is no conflict of interest.

**Author details**

1 Department of Microbiology, University of Lagos, Lagos, Nigeria. 2 Molecular Biology and Biotechnology Department, Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria.

**References**

1. Podschun R, Ullmann U. *Klebsiella* spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods and pathogenicity factors. Clin Microbiol Rev. 1998;11(4):589–603.
2. Omorogie R, Igbaramah IO, Egbe CA, Ogefere OH. Urinary tract infection among neonates in Benin City Nigeria. GMBHS. 2012;4:118–21.
3. Li J, Huang Z-Y, Yu T, Tao X-Y, Hu Y-M, Wang HC, Zou M-X. Isolation and characterization of a sequence type 25 carbapenem-resistant hyper-virulent *Klebsiella pneumoniae* from mid-south region of China. BMC Microbiol. 2019;19:219.
4. Benggochea JA, Pessaio JS. *Klebsiella pneumoniae* infection biology; living to counteract host defenses. FEMS Microbiol Rev. 2019;43(2):123–44.
5. Rath S, Padhy RN. Prevalence of two multidrug-resistant *Klebsiella* species in an Indian teaching hospital and adjoining community. J Infect Public Heal. 2014;7:496–507.
6. Fadeyi A, Zumuk CP, Raheem RA, Nwangwaisi C, Desalu OO. Prevalence and antibiotic susceptibility pattern of ESBL producing *Klebsiella* isolated from clinical specimens in a Nigerian tertiary hospital Afr J Infect Dis. 2016;10(1):32–7.
7. Dumaru R, Baral R, Shrestha LB. Study of biofilm formation and antibiotic resistance pattern of Gram negative bacilli among the clinical isolates at BPKIHS, Dharan. BMC Res Notes. 2019;12:38.
8. Reza A, Sutton JM, Rahman KM. Effectiveness of efflux pump inhibitors as biofilm disruptors and resistance breakers in Gram negative (ESKAPE) bacteria. Antibiotics. 2019;8:229.
9. Martins M, Vieiros M, Couto I, Costa SS, Pacheco T, Fanning S, Pages JM, Amaral L. Identification of efflux pump mediated multidrug resistant bacteria by ethidium bromide agar cartwheel method. In vivo. 2011;25:171–8.
10. Cheesebrough M. *Escherichia coli* District laboratory practice in tropical countries. Part 2. 2nd ed. London: Cambridge University Press; 2006. p. 178–80.
11. EUCAST. The European Committee on Antimicrobial Susceptibility Testing. Break point tables for interpretation of MICs and zone diameters version 9.0. 2019; http://www.eucast.org. Accessed 10 July 2019.
12. Stephanovic S, Vukovic D, Dacic I, Savic B, Svabic-Vlahovic B. A modified microtiter-plate test for quantification of staphylococcal biofilm formation. J Microbiol Methods. 2000;40(2):175–9.
13. Vuotto C, Longo F, Balice MP, Donelli G, Varaldo PE. Antibiotic resistance related to biofilm formation in *Klebsiella pneumoniae*. Pathog. 2014;3:743–58.
14. Calfee DP. Recent advances in the understanding and management of *Klebsiella pneumoniae* [version 1; referees: 2 approved]. F1000 Res. 2017;6:1760.
15. Sarge OO, Queenan AM, Ojo KK, Adeniyi BA, Roberts MGT. Urinary tract infection among symptomatic outpatients visiting a tertiary hospital based in Midwestern Nigeria. Glob J Health Sci. 2013;5(2):187–99.
16. Akinduti PA, Olashinde GI, Ejiule O, Taiwo OS, Obafemi YD. Fecal carriage and phylodiversity of community acquired bla TEM Enteric bacilli in Southwest Nigeria. Infect Drug Resist. 2018;11:2425–33.
17. Oli AGN, Ogbedeagru VL, Ejiekwu CP, Iroha IR, Ugwu MC, Ofomata CM, Okeke KN, Emenehbe GO, Okoro JC, Kansi CO, Onah SK. Multi-antibiotic resistance and factors affecting carriage of extended spectrum *β*-lactamase-producing enterobacteriaceae in pediatric population of Enugu metropolis, Nigeria. Med Sci. 2019;7:104.
18. Huai W, Ma QB, Zhao Y, Zhai QR. Distribution and drug resistance of pathogenic bacteria in emergency patients. World J Clin Cases. 2019;7(20):3175–84.
19. Yazdanestad S, Alkudhairy MK, Najafpour R, Farajtabrizi E, Al-Mosawi RM, Sakhi M, Jafarzadeh E, Izadpour F, Ameri A. Preliminary survey of extended-spectrum *β*-lactamases (ESBLs) in nosocomial uropathogen *Klebsiella pneumoniae* in north-central Iran. Helion. 2019;5:e02349.
21. Humayun A, Siddiqui FM, Akram N, Saleem S, Ali A, Iqbal T, Kumar A, Kamran R, Bohari H. Incidence of metallo-beta-lactamase-producing Klebsiella pneumoniae isolates from hospital setting in Pakistan. Int Microbiol. 2018. https://doi.org/10.1007/s10123-018-0006-1.

22. Szabo O, Kocsis B, Szabo N, Kschoe K, Szabo D. Contribution of OqxAB Efflux Pump in Selection of Fluoroquinolone-Resistant Klebsiella pneumoniae. Can J Infect Dis Med Microbiol. 2018. https://doi.org/10.1155/2018/4271638.

23. Maurya N, Jangra M, Tambat R, Nandanwar H. Alliance of efflux pumps with β-Lactamases in multidrug-resistant Klebsiella pneumoniae isolates. Microb Drug Resist. 2019;25(8):1155–63.

24. Nirwati H, Sinanjung K, Fahrniss F, Wijaya F, Napitupulu S, Hati VP, Hakim MS, Melsal A, Aman AF, Nuryastuti T. Biofilm formation and antibiotic resistance of Klebsiella pneumoniae isolated from clinical samples in a tertiary care hospital, Klaten, Indonesia. BMC Proc. 2019;13:20.

25. Alcántar-Curiel MD, Ledezma-Escamante CA, Jarillo-Quijada MD, Gayosso-Vázquez C, Morf-n-Otero R, Rodríguez-Noriega E, Cedillo-Ramirez ML, Santos-Preciado JJ, Giron JA. Association of antibiotic resistance, cell adherence, and biofilm production with the endemicity of nosocomial Klebsiella pneumoniae. Biomed Res Int. 2018. https://doi.org/10.1155/2018/7012958.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.